The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
RummelM.J.NiederleN.MashmeyerG.Bendamustine plus rituximab (B-R) versus CHOP plus rituximah (CHOP_R) as first line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 Study. Proc Am Soc Clin Oncol.2012. Abstract 3. http://abstract.asco.org/AbstView_114_95807.html. Accessed June 12, 2012.
WeidmannE.NeumannA.FauthF.Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol.2011; 22(8): 1839–1844.
6.
FischerK.CramerP.BuschR.Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol.2011; 29(26): 3559–3566.
7.
RummelM.J.Al-BatranS.E.KimS.Z.Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol.2005; 23(15): 3383–3389.
8.
OguraM.AndoK.NiitsuN.A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Troc Am Soc Clin Oncol.2010. Abstract 8023. http://abstract.asco.org/AbstView_114_96015.html. Accessed May 25, 2012.
SehnL.DonaldsonJ.FilewichA.Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood.2007; 109: 4171–4173.
12.
ZahraniA.IbrahimN.EidA.Case report: rapid infusion rituximab changing practice for patient care. J Oncol Pharm.2009; 15: 183–186.
13.
HeskethP.J.KrisM.G.GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
18.
CarmichaelJ.KeizerH.J.CupissolD.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
19.
de WitR.de BoerA.C.vd LindenG.H.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85(8): 1099–1101.
SmithT.KhatcheressianJ.LymanG.2006Update of recommendations for the use of white blood cell growth factors: an evidence based clinical practice guideline, http://jco.ascopubs.org/content/24/19/3187.full.pdf. Accessed July 24, 2012.
22.
RamasamyK.HazelB.MahmoodS.Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Hematol.2011; 155(5): 632–634.
23.
SchoppmeyerK.KrethF.WiedmannM.A pilot study of bendamustine in advanced bile duct cancer. Anti-Cancer Drugs.2007; 18(6): 697–702.
